Clopidogrel only — Competitive Intelligence Brief

Clopidogrel only (Clopidogrel only) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist / Thienopyridine antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Clopidogrel only (Clopidogrel only) — Seung-Jung Park. Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, preventing blood clots.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel only TARGET	Clopidogrel only	Seung-Jung Park	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Switch ticagrelor to clopidogrel	Switch ticagrelor to clopidogrel	The First Affiliated Hospital with Nanjing Medical University	marketed	P2Y12 receptor antagonist; antiplatelet agent	P2Y12 receptor
prasugrel/bivalirudin	prasugrel/bivalirudin	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Antiplatelet agent + Direct thrombin inhibitor combination	P2Y12 receptor (prasugrel); Thrombin (bivalirudin)
Clopidogrel reloading	Clopidogrel reloading	University of Pecs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Aspirin combined with clopidogrel	Aspirin combined with clopidogrel	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Dual antiplatelet agent	Cyclooxygenase (COX) and P2Y12 receptor
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Aspirin and Clopidogrel	Aspirin and Clopidogrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy)	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist / Thienopyridine antiplatelet agent class)

1. Azienda Policlinico Umberto I · 1 drug in this class
2. Hospital Central San Luis Potosi, Mexico · 1 drug in this class
3. Sanofi · 1 drug in this class
4. Seung-Jung Park · 1 drug in this class
5. Stiftung Institut fuer Herzinfarktforschung · 1 drug in this class
6. US Department of Veterans Affairs · 1 drug in this class
7. University of Pecs · 1 drug in this class
8. VA Office of Research and Development · 1 drug in this class